Reviva Pharmaceuticals (RVPH) News Today $1.31 -0.07 (-5.07%) (As of 04:29 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period Reviva Pharmaceuticals Holdings, Inc. (RVPHW)September 12, 2024 | ca.finance.yahoo.comReviva Pharmaceuticals Holdings (RVPH) Earnings Dates & ReportsSeptember 12, 2024 | investing.comReviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in SchizophreniaSeptember 9, 2024 | finanznachrichten.deReviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in SchizophreniaSeptember 9, 2024 | markets.businessinsider.comRVPH Jan 2026 5.000 callSeptember 8, 2024 | ca.finance.yahoo.comReviva to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comRVPH: August OLE UpdateAugust 27, 2024 | msn.comExplainer-Big Tech wants AI to be regulated. Why do they oppose a California AI bill?August 21, 2024 | msn.comReviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq RulesAugust 21, 2024 | globenewswire.comMaxim Group Downgrades Reviva Pharmaceuticals Holdings (RVPH)August 17, 2024 | msn.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q2 2024August 14, 2024 | investorplace.comReviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary FibrosisAugust 6, 2024 | finance.yahoo.comReviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary HypertensionJuly 9, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 30, 2024 | prnewswire.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | finance.yahoo.comReviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 29, 2024 | globenewswire.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | finance.yahoo.comReviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 28, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 23, 2024 | prnewswire.comRVPH: Enrollment Right Around the CornerMay 22, 2024 | finance.yahoo.comReviva to Participate in the BIO International ConventionMay 21, 2024 | globenewswire.comReviva Pharmaceuticals Holdings, Inc.May 20, 2024 | edition.cnn.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 16, 2024 | prnewswire.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15, 2024 | finance.yahoo.comReviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in SchizophreniaMay 15, 2024 | globenewswire.comRVPH Stock Earnings: Reviva Pharmaceuticals Beats EPS for Q1 2024May 14, 2024 | investorplace.comReviva Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 14, 2024 | globenewswire.comReviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International ConferenceMay 13, 2024 | globenewswire.comRVPH INVESTOR NOTICE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation - RVPHMay 10, 2024 | prnewswire.comReviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual MeetingMay 9, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHMay 6, 2024 | prnewswire.comReviva Pharmaceuticals Holdings Inc Ordinary Shares RVPHMay 4, 2024 | morningstar.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reviva Pharmaceuticals Holdings, Inc. - RVPHApril 28, 2024 | stockhouse.comRVPH: Full Year 2023 ResultsApril 25, 2024 | finance.yahoo.comRVPH LOSS ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Reviva Pharmaceuticals Holdings, Inc. Investors to Inquire About Securities Class Action Investigation – RVPHApril 25, 2024 | businesswire.comBrokers Set Expectations for Reviva Pharmaceuticals Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Equities research analysts at HC Wainwright cut their Q1 2024 EPS estimates for shares of Reviva Pharmaceuticals in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now eApril 24, 2024 | marketbeat.comHC Wainwright Weighs in on Reviva Pharmaceuticals Holdings, Inc.'s Q1 2025 Earnings (NASDAQ:RVPH)Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a research note issued on Monday, April 22nd. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.33) per sApril 23, 2024 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)April 22, 2024 | markets.businessinsider.comReviva Pharmaceuticals (NASDAQ:RVPH) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Reviva Pharmaceuticals in a report on Monday.April 22, 2024 | marketbeat.comReviva Pharmaceuticals' (RVPH) "Speculative Buy" Rating Reiterated at BenchmarkBenchmark reissued a "speculative buy" rating and issued a $17.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday.April 16, 2024 | marketbeat.comRVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER DataApril 15, 2024 | msn.comRVPH Stock Earnings: Reviva Pharmaceuticals Misses EPS for Q4 2023April 15, 2024 | investorplace.comReviva Pharmaceuticals: Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | finanznachrichten.deReviva Pharmaceuticals: Reviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 15, 2024 | finanznachrichten.deReviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in SchizophreniaApril 15, 2024 | globenewswire.comReviva Reports Full Year 2023 Financial Results and Recent Business HighlightsApril 15, 2024 | globenewswire.comReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Short Interest UpdateReviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 1,060,000 shares, a growth of 62.9% from the March 15th total of 650,700 shares. Based on an average daily volume of 331,800 shares, the days-to-cover ratio is currently 3.2 days.April 14, 2024 | marketbeat.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 28, 2024 | finance.yahoo.comReviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual MeetingMarch 28, 2024 | globenewswire.com Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Biden's Executive Order, Dems Digital Money Legislation, First Step To (Ad)Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it. This means you must act NOW before it's too late. RVPH Media Mentions By Week RVPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVPH News Sentiment▼-0.250.44▲Average Medical News Sentiment RVPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVPH Articles This Week▼02▲RVPH Articles Average Week Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: PRQR News LFCR News ADVM News ME News CRDL News ELUT News OPTN News RANI News FBLG News IMUX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVPH) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
